최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0099562 (2013-12-06) |
등록번호 | US-8987237 (2015-03-24) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 10 인용 특허 : 520 |
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estra
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
1. A pharmaceutical composition comprising: a solubilizing agent comprising: mono- and diglycerides of capric and caprylic acid; andat least one of lauroyl macrogol-32 glycerides EP, lauroyl polyoxyl-32 glycerides NF, or lauroyl polyoxylglycerides;progesterone; andestradiol, the estradiol being at l
1. A pharmaceutical composition comprising: a solubilizing agent comprising: mono- and diglycerides of capric and caprylic acid; andat least one of lauroyl macrogol-32 glycerides EP, lauroyl polyoxyl-32 glycerides NF, or lauroyl polyoxylglycerides;progesterone; andestradiol, the estradiol being at least about 90% solubilized in the solubilizing agent;wherein the estradiol and the progesterone are present in the solubilizing agent, and the estradiol and suspended progesterone are uniformly dispersed. 2. The pharmaceutical composition of claim 1, wherein the ratio of progesterone to estradiol is from about 24:1 to about 200:1. 3. The pharmaceutical composition of claim 2, wherein the ratio of progesterone to estradiol comprises one of: about 24:1, about 25:1, about 96:1, about 100:1, about 192:1, and about 200:1. 4. The pharmaceutical composition of claim 1, wherein the progesterone is between about 7.14% w/w and about 33.33% w/w of the pharmaceutical composition. 5. The pharmaceutical composition of claim 1, wherein the estradiol is between about 0.12% w/w and about 0.35% w/w of the pharmaceutical composition. 6. The pharmaceutical composition of claim 1, wherein the composition is encapsulated in a gelatin capsule; and wherein each gelatin capsule comprises from about 25 mg to about 200 mg of progesterone and from about 0.125 mg to about 2.00 mg of estradiol. 7. The pharmaceutical composition of claim 1, wherein the estradiol is at least 90% solubilized in the solubilizing agent. 8. A pharmaceutical composition comprising: a solubilizing agent comprising: monoglycerides and diglycerides of caprylic and capric acid; anda polyethylene glycol glyceride;progesterone; andestradiol, the estradiol being at least about 90% solubilized in the solubilizing agent;wherein the estradiol and the progesterone are present in the solubilizing agent, and the estradiol and progesterone are uniformly dispersed. 9. The pharmaceutical composition of claim 8, wherein the ratio of progesterone to estradiol is from about 24:1 to about 200:1. 10. The pharmaceutical composition of claim 9, wherein the ratio of progesterone to estradiol comprises one of: about 24:1, about 25:1, about 96:1, about 100:1, about 192:1 and about 200:1. 11. The pharmaceutical composition of claim 8, wherein the progesterone is between about 7.14% w/w and about 33.33% w/w of the pharmaceutical composition. 12. The pharmaceutical composition of claim 8, wherein the estradiol is between about 0.12% w/w and about 0.35% w/w of the pharmaceutical composition. 13. The pharmaceutical composition of claim 8, wherein the composition is encapsulated in a gelatin capsule; and wherein each gelatin capsule comprises from about 25 mg to about 200 mg of progesterone and from about 0.125 mg to about 2.00 mg of estradiol. 14. The pharmaceutical composition of claim 8, wherein the estradiol is at least 90% solubilized in the solubilizing agent. 15. A pharmaceutical composition comprising: a solubilizing agent comprising: mono- and diglycerides of capric and caprylic acid; andat least one of lauroyl macrogol-32 glycerides, lauroyl polyoxyl-32 glycerides, and lauroyl polyoxylglycerides;progesterone; andestradiol, the estradiol being at least about 90% solubilized in the solubilizing agent;wherein the estradiol and the suspended progesterone are present in the solubilizing agent, and the estradiol and suspended progesterone are uniformly. 16. The pharmaceutical composition of claim 15, wherein the ratio of progesterone to estradiol is from about 24:1 to about 200:1. 17. The pharmaceutical composition of claim 15, wherein the ratio of progesterone to estradiol comprises one of: about 24:1, about 25:1, about 96:1, about 100:1, about 192:1 and about 200:1. 18. The pharmaceutical composition of claim 15, wherein the progesterone is between about 7.14% w/w and about 33.33% w/w of the pharmaceutical composition. 19. The pharmaceutical composition of claim 15, wherein the estradiol is between about 0.12% w/w and about 0.35% w/w of the pharmaceutical composition. 20. The pharmaceutical composition of claim 15, wherein the composition is encapsulated in a gelatin capsule; and wherein each gelatin capsule comprises from about 25 mg to about 200 mg of progesterone and from about 0.125 mg to about 2.00 mg of estradiol.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.